Close

Pfizer (PFE) RAPAMUNE sNDA Accepted for FDA Priority Review

February 20, 2015 10:30 AM EST Send to a Friend
Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental New ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login